The small business innovation research (SBIR) grant will enable Sequella to perform investigational new drug-directed preclinical in vitro and in vivo potency, pharmacology, and toxicity studies of SQ609, both as a single agent and in combination with other more established therapies.
Carol Nacy, CEO of Sequella, said: “We are grateful that the grant reviewers recognized the potential of this new antibiotic class, and its lead representative drug compound SQ609, and we appreciate National Institute of Allergy and Infectious Diseases (NIAID) support of these important preclinical studies with SBIR funding.
“The SBIR grant program at the National Institutes of Health (NIH) serves a vital role in assisting companies to develop new antibiotics for important infectious diseases that impact US public health.”